| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 21 Jun 2025 | 21 Jun 2025 |
| Outcome of Board Meeting held on June 21, 2025 | ||
| Board Meeting | 22 May 2025 | 13 May 2025 |
| Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Audited financial results (standalone and consolidated) for the quarter and year ended March 31 2025 and recommendation of Final Dividend if any. Board of Directors of the Company at its meeting held today i.e. Thursday, May 22, 2025, has inter-alia transacted and approved/ recommended the following businesses: Recommended a final dividend of Rs. 3 / - (Rupees Three only) per equity share of Rs. 10 /- (Rupees Ten only) each of the Company (at the rate of 30%) for the financial year ended March 31, 2025, subject to approval of the Members of the Company at the ensuing Annual General Meeting of the Company. Dividend, once approved by the Members, shall be paid within the prescribed timeline under the Companies Act, 2013. Outcome of Board Meeting held on May 22, 2025: 1. Audited Financial Results (standalone and consolidated) for the quarter and year ended March 31, 2025. 2. Dividend 3. Re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company 4. Appointment of Secretarial Auditors of the Company 5. Incorporation of a wholly-owned Subsidiary by the name Emcure Generics Private Limited in Pune, Maharashtra, India Read less.. Intimation of proposed incorporation of a Wholly-owned Subsidiary by the name Emcure Generics Private Limited Re-appointment of Dr. Mukund Gurjar as a Whole-time Director of the Company. (As Per BSE Announcement Dated on 22.05.2025) | ||
| Board Meeting | 6 Feb 2025 | 24 Jan 2025 |
| Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31 2024. The trading window for dealing in securities of the Company by the Designated Persons and their relatives has been already closed from January 01 2025 as communicated earlier vide our letter No. EPL/CS/SE/0033/2024 dated December 18 2024 and shall remain closed till 48 hours after the declaration of the financial results i.e. till February 08 2025 in terms of the Companys Code of Conduct for regulating monitoring and reporting of insider trading in the securities of the Company framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 as amended. Unaudited Financial Results (Consolidated & Standalone) For the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 06/02/2025) | ||
| Board Meeting | 7 Nov 2024 | 29 Oct 2024 |
| Quarterly Results Outcome of Board Meeting held on November 7, 2024 (As per BSE Announcement Dated on 07/11/2024) | ||
| Board Meeting | 13 Aug 2024 | 6 Aug 2024 |
| Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30 2024. The Board of Directors of the Company at its meeting held today i.e. Tuesday, August 13, 2024 has inter-alia approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, as reviewed and recommended by the Audit Committee. Pursuant to Regulation 33 of the Listing Regulations, we are enclosing herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, along with the Limited Review Reports on the aforesaid Results as issued by B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, is also enclosed herewith as Annexure B. (As Per Bse Announcement Dated on 13.08.2024) | ||
According to Emcure, the deal was cleared by its board and will be settled in cash. The payments may happen in one or more parts, depending on the closure timeline.
EBITDA margin slightly declined, down 80 basis points to 20.8% in Q2, reflecting some operational pressures.
The allotment of shares was finalised on July 8, and Emcure Pharma shares were scheduled to be listed on the BSE and NSE on July 10.
The IPO comprised a mix of fresh equity sale and an offer for sale (OFS).
The categories earmarked for NII and QIB investors received the most subscriptions, at 47.98 and 193.06 times, respectively.
The IPO is priced between Rs 960 and Rs 1008 a share, with buyers able to bid for 14 shares per lot.
According to BSE data, the initial share sale attracted bids for 1,80,40,960 shares, with 1,37,03,538 shares on offer.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
